One‐Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point‐of‐Care Testing
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.70115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Zihao Fan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Hepatitis E virus, Point-of-Care Testing, Hepatitis E, RNA, Viral. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was supported by the National Natural Science Foundation of China (82002243, 82100653), Key Projects of the Beijing Municipal Education Commission's…, Capital Medical University.
Abstract (Originalsprache)
Hepatitis E virus (HEV) poses a serious threat to both public health and animal food safety, thereby highlighting the demands for rapid, sensitive, and easy‐to‐use detection. This study aimed to develop a One‐Pot assay using CRISPR/Cas13a for detecting HEV RNA, suitable for point‐of‐care testing (POCT) in resource‐limited settings. CRISPR/Cas13a combined with reverse transcription polymerase chain reaction (RT‐PCR) and reverse transcription recombinase‐aided amplification (RT‐RAA) was applied to a One‐Pot assay device. Additionally, a large cohort of HEV‐infected patient (154) and animal (104) specimens was utilized for validation. The RT‐PCR/RT‐RAA + CRISPR/Cas13a assays for HEV RNA detection (genotypes: HEV‐1, HEV‐3, and HEV‐4) were established, optimized, and validated, achieving a limit of detection (LoD) of 1 copy/μL and 100% specificity. In the application validation for HEV infection, the positive rates of the RT‐PCR + CRISPR and RT‐RAA + CRISPR assays were 98.6% and 89.6% for patients, and 96.6% and 88.8% for animals, respectively, which were superior to those of RT‐qPCR. Furthermore, sample rapid lysis, reagent lyophilization, and the One‐Pot device were integrated to construct a One‐Pot assay with an LoD of 10 2 copies/μL. Despite slight decreases in sensitivity, the One‐Pot assay significantly reduces the assay time to 35 min, making it easy to perform, minimizing contamination, and meeting the requirements for screening. We developed a One‐Pot assay of HEV RNA using the CRISPR/Cas13a which effectively realizes a POCT test and maximizes the impetus for POCT implementation and shows potential as a valuable tool for detecting and monitoring HEV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
- Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People's Republic of China.
- NYU Langone Medical Center, New York University School of Medicine, New York City, New York, USA.
Förderung
- This study was supported by the National Natural Science Foundation of China (82002243, 82100653), Key Projects of the Beijing Municipal Education Commission's…
- Capital Medical University
Zitieren
APA
Fan, Z., Xu, L., Cao, Y., Liu, T., Tian, Y., Pan, Z., Mo, Y., Wang, X., Zhu, X., Gao, Y., Zhang, X., Pan, C. Q., Wang, L., & Ren, F. (2024). One‐Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point‐of‐Care Testing. Journal of Medical Virology. https://doi.org/10.1002/jmv.70115
Vancouver
Fan Z, Xu L, Cao Y, Liu T, Tian Y, Pan Z, et al. One‐Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point‐of‐Care Testing. Journal of Medical Virology. 2024. doi:10.1002/jmv.70115
BibTeX
@article{Fan2024,
author = {Fan, Zihao and Xu, Ling and Cao, Yaling and Liu, Tianxu and Tian, Yuan and Pan, Zhenzhen and Mo, Yinkang and Wang, Xinyu and Zhu, Xianru and Gao, Yao and Zhang, Xiangying and Pan, Calvin Q and Wang, Lin and Ren, Feng},
title = {One‐Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point‐of‐Care Testing},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.70115}
}
EUVIMED